CDRE CADRE HOLDINGS INC
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 9 analyst firms say about CADRE HOLDINGS INC: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
7 rated views · 9 analyst/firm records · 9 firms
Radar score
- Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8053
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8053
Recent analyst activity · last 90 days
Our tracked history has 8 reports on CDRE from 7 analyst firms in the last 90 days (10 firms in the past year).
Comparing each firm's latest target with its previous one: 1 lowered it, 2 left it unchanged and 2 have their first observed target in the past year.
No firm's latest available rating differs from its previous one.
Latest observed target change: JP Morgan lowered its target from $45.00 (set 7 Aug 2026) to $35.00 on 13 Oct 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| B Riley Securities | Jeffrey W Van Sinderen | Buy | 12 Oct 2026 | — |
| Cjs Securities | Unnamed analyst | Buy | 11 Dec 2025 | — |
| Jefferies | Sheila Kahyaoglu | Buy | 13 May 2026 | 43.00 USD |
| JPMorgan | Tomohiko Sano | Buy | 13 Oct 2026 | 35.00 USD |
| Lake Street Capital Markets | Mark Smith | Buy | 12 May 2026 | 53.00 USD |
| Roth Capital | Matt Koranda | Buy | 10 Aug 2026 | 43.00 USD |
| UBS | Unnamed analyst | — | 10 Aug 2026 | 43.00 USD |
| Weiss Ratings | Unnamed analyst | — | 17 Aug 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 4 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:07 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.